Mebufotenin (5-MeO-DMT) vs Psilocybin (COMP360)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

Mebufotenin (5-MeO-DMT) · GH001

Developed by GH Research

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT05800860 · Phase 2 · completed

This randomized, quadruple-masked, placebo-controlled phase 2 trial assigned 81 patients with treatment-resistant depression to inhaled GH001 (mebufotenin) or placebo. The registered primary endpoint was the change in MADRS depression score from baseline to Day 7. The sponsor reported a placebo-adjusted reduction of 15.5 points at Day 8 (P<0.0001), so the primary endpoint was met. This result comes from a company filing and is not posted on ClinicalTrials.gov, and no power calculation was found.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Mean change in MADRS from Baseline to Day 7: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) (met)

Result source: NCT05800860

Psilocybin (COMP360)

Developed by COMPASS Pathways

Phase 3 in Major Depressive Disordersmall molecule
Reliable signal

NCT05711940 · Phase 3 · active, not recruiting

This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2029 · NCT06132178 (registry estimate)

Reported efficacy

COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. (Week 6): COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. (met)

Result source: NCT05711940

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMebufotenin (5-MeO-DMT)Psilocybin (COMP360)
MADRS, change (acute)—Not reported-12 vs -6.8−5.2 vs placebo25 mg · wk 3 · n 79NCT03775200
CGI-S, change (acute)—Not reported—Not posted · NCT05624268
MADRS response—Not reported—Not posted · NCT05624268
MADRS remission—Not reported—Not posted · NCT05624268
Relapse (% of patients)—Not reported—Not posted · NCT05624268

MADRS, change (acute)

Mebufotenin (5-MeO-DMT)
—Not reported
Psilocybin (COMP360)
-12 vs -6.8−5.2 vs placebo25 mg · wk 3 · n 79NCT03775200

CGI-S, change (acute)

Mebufotenin (5-MeO-DMT)
—Not reported
Psilocybin (COMP360)
—Not posted · NCT05624268

MADRS response

Mebufotenin (5-MeO-DMT)
—Not reported
Psilocybin (COMP360)
—Not posted · NCT05624268

MADRS remission

Mebufotenin (5-MeO-DMT)
—Not reported
Psilocybin (COMP360)
—Not posted · NCT05624268

Relapse (% of patients)

Mebufotenin (5-MeO-DMT)
—Not reported
Psilocybin (COMP360)
—Not posted · NCT05624268
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Mebufotenin (5-MeO-DMT): 1 of 5 rows · Psilocybin (COMP360): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMebufotenin (5-MeO-DMT)Psilocybin (COMP360)
MADRS
absolute change · score
No placebo or comparator arm
-15.5 score @ 1.142857wka,b,c,d
NCT05800860 · Phase 2 · sponsor-reported, not registry data
-3.6 score @ 6wkCOMP360 25 mga,b,c,d
NCT05624268 · Phase 3 · sponsor-reported, not registry data
Dropout rate—
0%25 mge
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
6.3%25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
—25 mge
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
—25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Serious AEs—
0%25 mge
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
6.3%25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
25 mge
headache 31.6%
blood pressure increased 15.8%
depression 5.3%
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
25 mg
headache 34.2% (placebo 25.3%)
nausea 22.8% (placebo 5.1%)
fatigue 15.2% (placebo 8.9%)
NCT03775200 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 1.142857 weeks versus 6 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Psilocybin (COMP360)

MADRS 42.1% (n=19) @ 3wk25 mg
responder rate · % of participants
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
MADRS Remission 42.1% (n=19) @ 3wk25 mg
responder rate · % of participants
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
CGI-S -1.3 score @ 3wk25 mg
absolute change · score
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence
MADRS -12 vs -6.8 placebo score @ 3wk25 mg
absolute change · score
NCT03775200 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mebufotenin (5-MeO-DMT)'s landscape · Psilocybin (COMP360)'s landscape